Articles On Race Oncology (ASX:RAC)

The S&P ASX 200 Health Care index fell 13.21% in August as a tough reporting season weighed on sector CSL had its biggest ever one day fall on August 19, down 17% following softer FY25 results and restructure plans Despite the broader...

Perversely, Polynovo stands to benefit from a US reimbursement cut for outpatients ASX biotechs had a poor August, but they will Spring into action Race Oncology opens Hong Kong site in “cautious” trial rollout   PolyNovo (ASX:PNV) shares...

Ignite Partners is bringing the buzz to Hong Kong with a two-day power event packed with dynamic one-on-ones between top CEOs and hand-picked investors. The Grand Ballroom, 1 Harbour Road, Wan Chai, Hong Kong 15 – 16 October 2025 Pre-ar...

Highlights US policy changes back research on rare diseases Australian biotech firms gain momentum New regulatory clarity benefits orphan drug development Australian biotech companies focused on rare disease therapies are gaining...

MoneyTalks is Stockhead’s drill down into what stocks investors are looking at right now. We tap our list of experts to hear what’s hot, their top picks and what they’re looking out for. Today we hear from Australia’s Summit Biotech Fund ma...

The S&P ASX 200 Health Care index rose 9.05% in July with rotation into the sector gaining momentum  Lumos soared 170% in July after six-year exclusive deal valued at up to US$317 million with PHASE Scientific for distribution of Febri...

Highlights Breaks down biotech company stages from discovery to commercialisation Explores real-world examples of ASX-listed biotech companies Offers insight into navigating risk across drug development phases Biotech investing is...

Race Oncology (ASX:RAC) has captured the most attention on the HotCopper forums today after successfully – and safely – dosing its first patient with RC220 and RC220 in combination with doxorubicin. Listen to the HotCopper podcast for in...

Trigg Minerals (ASX:TMG) has drawn the most attention on the HotCopper forums through Thursday trade after the mining company mysteriously halted just before open. Holders were left “a bit worried” across the boards. Listen to the HotCop...

The ASX 200 Health Care Index fell 1.05% in June and remains the worst performing sector YTD down 6.64% Morgans healthcare analyst Iain Wilkie said June likely saw some tax loss selling before EOFY  Amplia up 300% in June after complete re...

In this HotCopper Capital Compass interview, Race Oncology (ASX:RAC) chairman Dr Pete Smith discusses the company’s “safe and successful” Phase One clinical trials and the RC220 plus doxorubicin dosing done at the time. Listen to the Hot...

Amplia Therapeutics (ASX:ATX) has been the most watched on HotCopper forums through today after huge results from its ACCENT trials set up to look into how its FAK inhibitor, Narmafotinib, combats cancer. Listen to the HotCopper podcast...

Highlights ASX 200 futures hint at a soft open amid global macro caution Fed maintains interest rates; inflation outlook revised upward Small-cap actions drive interest with regulatory approvals, trial updates The Australian share...

The S&P/ASX 200 Health Care Index rose 1.59% in May but remains worst performing sector YTD down 5.65% Morgans healthcare analyst Iain Wilkie said US President Donald Trump’s trade and health policies continue to impact sector Lumos up...

Tylah Tully speaks with Race Oncology (ASX:RAC) CEO Daniel Tillett after the company dosed the first patient in its RC220 Phase 1 solid tumour trial. Race has reformulated RC220, after the initial formulation caused crystallisation in the b...

Global pharmaceutical leader Herwig Janssen appointed Tryptamine non-executive chairman Janssen held senior leadership roles with multinational pharmaceutical company Johnson & Johnson Chris Ntoumenopoulos will transition to role of ex...

Tryptamine is focused on using psilocybin to treat difficult mental health and neurological conditions In league with Swinburne University, the company will launch a groundbreaking binge eating disorder trial using intravenous delivery Wit...

Highlights: ASX 200 futures edged higher in early trade, tracking gains from global equities and a strong US jobs report Positive sector moves led by information technology, real estate, and health care, while materials saw subdu...

Highlights Race Oncology appoints Dr Jose Iglesias as Chief Medical Officer and Dr Simon Fisher as Vice President of Clinical. RC220 development progresses with a focus on solid tumours and acute myeloid leukaemia. The leade...

The S&P/ASX 200 Health Care Index rose 2.16% in April with the S&P/ASX 200 rallying 3.6% Morgans healthcare analyst Iain Wilkie said April was a marked improvement on recent months Several approvals during April, including for EBR...

First patient dosed at lead trial site, Southside Cancer Care. Phase 1 trial to determine safety, tolerability and pharmacokinetic data, plus maximum tolerated combined dose of RC220 with chemotherapeutic doxorubicin. Up to 33 patients to...

The ASX200 closed up 0.24% at 8,145 points. The IT sector surged and was the best performer, up 4%, followed by Real Estate, up 1.6%, and Staples, up 1.4%. Energy shed some of yesterday’s gains and finished down, 1.35%, followed by Ma...

Highlights Race Oncology commences Phase 1 solid tumour trial with initial patient dosed safely at Miranda, NSW RC220 explored in combination with doxorubicin, leveraging prior bisantrene research and preclinical outcomes Tr...

Highlights ASX 200 advances as tech sector rallies and large-cap miners ease Andromeda achieves breakthrough in ultra-high purity alumina production Tesla leadership speculation rises amid US economic shifts and trade talks...

Telix’s quarterly sales reflect first revenue from the company’s recent purchase of a US nuclear medicine manufacturer Island Pharma hopes to lift the kimono on its dengue fever trial next month Race Oncology kicks off its cancer-busting,...

Highlights: Errawarra Resources advances its exploration at the Elizabeth Hill Silver Project Race Oncology expands its clinical trials with a new research site RareX pursues licensing for the Mrima Hill project in collabora...

The ASX200 has been flat, down 0.1% at 7,812 points in early afternoon trades. Errawarra Resources (ASX:ERW) has been among the most watched on HotCopper forums today after sharing details on the rapid advancement of its exploration prog...

Highlights  Wall Street downturn triggers expected dip in ASX open Global uncertainties, rate cut pressure shake investor sentiment Race Oncology advances cancer trial with new site activation  The Australian share market is expec...

Race Oncology activates first Australian site for Phase I trial of potential cancer and cardioprotective therapeutic RC220, enabling patient enrolments This comes after governance approval announced today, and Human Research Ethics Committ...

Donald Trump exempts “pharmaceuticals” from his tariff blitz ASX device makers mull their US manufacturing plans as Ansell shares plunge Race and Imugene progress their early-stage oncology trials   Liberation Day has spared the pharmaceu...

Highlights St George Mining Ltd announces a maiden Mineral Resource Estimate for the Araxá Project in Brazil, highlighting high-grade niobium and rare earths. ASX 200 futures show a modest gain as investors await updates from the...

  Southside Cancer Care Centre in Miranda initiated as first site for Race’s Phase I trial of RC220 in advanced solid tumours Race awaiting governance approval to activate site for patient recruitment Up to 53 patients to be enrolled in op...

Opthea shares enter trading halt on St Patrick’s Day ahead of a “material” trial update Imricor is on the hunt for funds, reportedly up to $80 million Race Oncology is in pole position for phase I trial start In the diabolically difficult...

Highlights: Opthea initiates a trading halt ahead of phase III clinical trial updates. Imricor Medical Systems advances funding efforts for US market entry. Race Oncology secures ethics approval for phase I trial of anti-can...

ASX bounces back with miners leading the charge US shutdown fears ease, giving markets a lift Myer and Liontown shine as big movers on the ASX   The ASX bounced back on Friday, shaking off a three-day losing streak and finishing 0.52% hig...

Bellberry Human Research Ethics Committee approves a Phase I trial of RC220 bisantrene in adult solid tumour patients Lead clinical site Southside Cancer Care Centre will start enrolling patients this month pending institutional approval a...

The ASX has been up as much as 0.45% at 7,783 points, breaking its Week 11 losing streak on the back of a rally in gold stocks. Materials has been the best performing sector, up 1.85%, followed by Utilities, up 1.4%, and Industrials, up...

Race Oncology Ltd (ASX:RAC) has been approved for its Phase One trial of its chemotherapeutic candidate RC220 to treat people with solid tumours. Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest he...

Good afternoon and welcome to HotCopper’s Market Close, I’m Jonathon Davidson. Doldrums remained the quo on Wednesday as tariff uncertainty once again shakes markets. The ASX pared some losses midday, perhaps because Trump’s congress spe...

Race executes work order contract with George Clinical to support Phase 1 trial of anticancer treatment RC220 Total cost of work order ~$8.6 million, with final trial cost to depend on number of recruited patients and other trial variables...

The S&P/ASX 200 Health Care Index fell 7.66% in February with the S&P/ASX 200 down 3.79% Morgans healthcare analyst Iain Wilkie said several factors caused investor jitters in February including job cuts to US FDA  Pacific Edge was...

ASX healthcare leaders are often involved in multiple companies or organisations  Syntara CEO Gary Philips believes seasoned executives can help develop the sector in Australia Dimerix CEO and MD Dr Nina Webster has two other key positions...

Highlights: Fisher & Paykel Healthcare (ASX:FPH) faces new tariffs but is adapting with strategic measures. Orthocell (ASX:OCC) is progressing with regulatory approvals in multiple markets. Life-sciences...

Stockhead’s Road to 2025 video series highlights companies’ key 2024 achievements and the routes they’re plotting towards a successful year ahead. In this episode, Fraser Palamara takes a look at Race Oncology (ASX:RAC), a biopharmaceutical...

The S&P/ASX 200 Health Care Index fell 1.85% in December but rose 7.51% overall in 2024  Mesoblast surged 52% in December after the US FDA approved its cell therapy Ryoncil for treatment of paediatric GvHD Percheron plunged 91% in Dece...

ASX gives back gains ahead of Fed decision Vulcan and DigiCo rise MinRes completes $780m gas deal with Hancock Prospecting   The ASX gave back its earlier gains this afternoon as investors adopted a more cautious approach ahead of the US...

Race Oncology has appointed experienced biotech executive Dr Megan Baldwin as a non-executive director Baldwin has more than 25 years’ experience in therapeutic drug development for oncology and opthalmology She is the founder and chief in...

ASX rises as banks lead, energy lags Bitcoin hits $107k… $150k target murmurings grow louder  Orica CEO to retire, Data#3 tumbles on Microsoft news   The ASX edged higher by 0.78% on Tuesday, with the big banks keeping the mood upbeat thr...

Vulcan Energy Resources Ltd (ASX: VUL) shares have returned from their trading halt on Friday with a thud. In morning trade, the ASX lithium stock's shares are down 12% to $5.82. Why is this ASX lithium stock crashing? The weakness in the V...

One ASX lithium stock refused to budge while the S&P/ASX 300 Index (ASX: XKO) limped lower today. Australian shares largely followed the mediocre example set by US markets last night. However, shares in Vulcan Energy Resources Ltd (...